Boman, Nea http://orcid.org/0000-0001-7613-3297
Fernandez-Luque, Luis http://orcid.org/0000-0001-8165-9904
Koledova, Ekaterina http://orcid.org/0000-0003-2572-9052
Kause, Marketta
Lapatto, Risto http://orcid.org/0000-0002-8030-2505
Funding for this research was provided by:
Merck Healthcare KGaA, an affiliate of Merck KGaA, Darmstadt, Germany
Article History
Received: 14 October 2019
Accepted: 7 April 2021
First Online: 26 April 2021
Declarations
:
: The ECOS study was conducted in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice (ICH-GCP E6) guidelines and applicable national legal and regulatory requirements. Written informed consent was obtained from patients (or their parent/guardian) prior to study enrolment. In order to allow statistical analysis of patient data, patients sign a user agreement before enrolling on easypod™ connect.
: Written informed consent for publication was obtained from either the patients or their parents/caregivers.
: NB and RL have no conflict of interest to report. LFL is General Manager of Salumedia Labs, a fully owned subsidiary of Adhera Health Inc. that is a precision digital therapeutics company based in Palo Alto (CA, USA). Salumedia Labs provides digital health services to the pharmaceutical industry, including Merck KGaA (Darmstadt, Germany). LFL is a shareholder of Adhera Health Inc. EK is an employee of Merck KGaA, Darmstadt, Germany. MK is an employee of Merck Oy Finland, Espoo, Finland (an affiliate of Merck KGaA, Darmstadt, Germany).